Elranatamab in Relapsed/Refractory Multiple Myeloma

Clinical trial NCT06711705 · RECRUITING

Trial details

NCT number: NCT06711705
Sponsor: University of California, San Diego
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Multiple Myeloma

Start date: 2024-12-18
Primary completion: 2029-12-01
Enrollment: 33

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.